At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 356 enrolled
Drug / intervention
Other: Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
In Brief
A Phase 2 clinical trial evaluating Other: Placebo, GSK232802, and 1 other intervention for Menopausal and Female Climacteric States. Completed, enrolled 356 participants across 87 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenopausal and Female Climacteric States
CountriesArgentina, Australia, Germany, Italy, New Zealand, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJan 2008
Primary CompletionJul 2008
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartJul 17, 2007
Primary CompletionJul 23, 2008
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 18.4 years ago
Interventions
Other: Placebodrug
GSK232802drug
PREMARINdrug